Is Prostate Cancer Stage Migration Continuing for Black Men in the PSA Era?

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2017 Jan 18

PMID 28094251

Citations 4

Authors

R W Dobbs

D T Greenwald

H Wadhwa

V L Freeman

M R Abern

Affiliations

Soon will be listed here.

Abstract

Background: In the United States, disease-specific mortality from prostate cancer (PC) is highest among black men. While the introduction of widespread PSA testing has been associated with a downward stage migration, whether this trend continues in the late PSA era and for black men is unknown. The objective of our study was to evaluate current PC stage migration patterns in the United States by race.

Methods: The Surveillance, Epidemiology and End Results (SEER) registry was queried to obtain all cases of PC reported between 2000 and 2013. Year of diagnosis was categorized into 2000-2003, 2004-2007, 2008-2010 and 2011-2013. Predictors of distant stage PC at diagnosis were determined using logistic regression adjusted for year of diagnosis, age at diagnosis, SEER region and race.

Results: A total of 791 184 PC cases were identified. The cohort comprised 78.9% (n=594 920) white and 14.1% (n=106 133) black men. The stage at diagnosis was 83.3% localized, 12.0% regional and 4.7% distant. Age-adjusted incidence demonstrated a steady decline for black men in all time groups while white men had a stable incidence of distant disease between 2000 and 2013. In univariate analysis, black men in the 2004-2007 (OR 0.86 (0.81-0.93)) and 2008-2010 cohorts (OR 0.85 (0.79-0.91)) were less likely to be diagnosed with metastatic PC as compared with the 2000-2003 baseline cohort. In multivariate analysis, the 2004-2007 black cohort was less likely to be diagnosed with distant PC (OR 0.90 (0.84-0.97)). This trend was not observed in white men who in multivariate analysis had an increased risk of distant PC in the 2004-2007 (OR 1.08 (1.04-1.11)), 2008-2010 (OR 1.22 (1.18-1.27)) and 2011-2013 (OR 1.65 (1.59-1.71)) groups.

Conclusions: PC downward stage migration continues in black men but not in white men. Discontinuation of PSA-based screening for PC could disproportionately affect black men.

Citing Articles

The Will Rogers phenomenon, breast cancer and race.

Nittala M, Mundra E, Packianathan S, Mehta D, Smith M, Woods W BMC Cancer. 2021; 21(1):554.

PMID: 34001038 PMC: 8127271. DOI: 10.1186/s12885-021-08125-8.

Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey.

Johnson J, Moser R, Ellison G, Martin D J Community Health. 2020; 46(2):389-398.

PMID: 33064229 DOI: 10.1007/s10900-020-00923-8.

Helping Men Find Their Way: Improving Prostate Cancer Clinic Attendance via Patient Navigation.

Dobbs R, Stinson J, Vasavada S, Caldwell B, Freeman V, Garvey D J Community Health. 2019; 45(3):561-568.

PMID: 31713018 DOI: 10.1007/s10900-019-00776-w.

Determinants of Clinic Absenteeism: A Novel Method of Examining Distance from Clinic and Transportation.

Dobbs R, Malhotra N, Caldwell B, Rojas R, Moreira D, Abern M J Community Health. 2017; 43(1):19-26.

PMID: 28551861 DOI: 10.1007/s10900-017-0382-z.

References

Stamey T, Yang N, Hay A, McNeal J, Freiha F, Redwine E . Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317(15):909-16. DOI: 10.1056/NEJM198710083171501. View

Potosky A, Miller B, Albertsen P, Kramer B . The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995; 273(7):548-52. View

Ross L, Berkowitz Z, Ekwueme D . Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008; 17(3):636-44. DOI: 10.1158/1055-9965.EPI-07-2709. View

Kutikov A, Cooperberg M, Paciorek A, Uzzo R, Carroll P, Boorjian S . Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis. 2012; 15(4):374-9. PMC: 3815610. DOI: 10.1038/pcan.2012.21. View

Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S . The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 2010; 25(1):21-7. DOI: 10.1007/s12149-010-0424-4. View

Mersha T, Abebe T . Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum Genomics. 2015; 9:1. PMC: 4307746. DOI: 10.1186/s40246-014-0023-x. View

Siegel R, Fedewa S, Miller K, Goding-Sauer A, Pinheiro P, Martinez-Tyson D . Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015; 65(6):457-80. DOI: 10.3322/caac.21314. View

Weiner A, Matulewicz R, Eggener S, Schaeffer E . Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016; 19(4):395-397. DOI: 10.1038/pcan.2016.30. View

Powell I, Bock C, Ruterbusch J, Sakr W . Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010; 183(5):1792-6. PMC: 3840791. DOI: 10.1016/j.juro.2010.01.015. View

10.

Moul J, Wu H, Sun L, McLeod D, Amling C, Lance R . Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 2002; 132(2):213-9. DOI: 10.1067/msy.2002.125315. View

11.

King H, Diamond E, LILIENELD A . Some epidemiological aspects of cancer of the prostate. J Chronic Dis. 1963; 16:117-53. DOI: 10.1016/0021-9681(63)90091-2. View

12.

Moyer V . Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157(2):120-34. DOI: 10.7326/0003-4819-157-2-201207170-00459. View

13.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

14.

Powell I, Vigneau F, Bock C, Ruterbusch J, Heilbrun L . Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prev. 2014; 23(8):1505-11. PMC: 4162307. DOI: 10.1158/1055-9965.EPI-13-1328. View

15.

Izawa J, Klotz L, Siemens D, Kassouf W, So A, Jordan J . Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J. 2011; 5(4):235-40. PMC: 3147035. DOI: 10.5489/cuaj.11134. View

16.

Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C . Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst. 2001; 93(3):219-25. DOI: 10.1093/jnci/93.3.219. View

17.

Carter H, Albertsen P, Barry M, Etzioni R, Freedland S, Greene K . Early detection of prostate cancer: AUA Guideline. J Urol. 2013; 190(2):419-26. PMC: 4020420. DOI: 10.1016/j.juro.2013.04.119. View

18.

Hebert J, Hurley T, Olendzki B, Teas J, Ma Y, Hampl J . Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst. 1998; 90(21):1637-47. DOI: 10.1093/jnci/90.21.1637. View

19.

Major J, Oliver M, Doubeni C, Hollenbeck A, Graubard B, Sinha R . Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study. Cancer Causes Control. 2012; 23(7):1185-91. PMC: 3405544. DOI: 10.1007/s10552-012-9988-8. View

20.

Noldus J, Graefen M, Haese A, Henke R, Hammerer P, Huland H . Stage migration in clinically localized prostate cancer. Eur Urol. 2000; 38(1):74-8. DOI: 10.1159/000020255. View